DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

More Industry Headlines

Award winners of 2017 A look back at this year's most distinguished award-winning individuals across the industry

Faster results are a patient priority: radiologists Patient portals represent a welcome shift from medicine's 'patriarchal' roots

Siemens Healthineers installs first two SOMATOM go.Up CT platforms in the U.S. Situated at CDI outpatient imaging facilities in Missouri

Five more organizations join NRHI's mission to measure total cost of health care in U.S. Data useful for providers, employers and policymakers

MR machine rented to scan single terrorist at Guantánamo doesn't work Liquid helium dissipated for unknown reasons

Alpha Source acquires BC Technical, doubles size Enables Alpha Source to expand its service offerings and geographical scope

Royal Philips and Nuance to enhance radiology reporting with AI technology Combines Philips Illumeo with adaptive intelligence and Nuance PowerScribe 360

MGH team develops a potential alternative to gadolinium-based contrast agents Made of the vital element manganese

Survey finds most patients prefer annual mammograms Challenges the USPSTF's recommendations

Multifunctional and retrofitted: What’s new in radiography and fluoroscopy High demand for multifunctional and retrofitted X-ray imaging solutions

BARDA's $60M plan to protect against radiation poisoning

by Brendon Nafziger , DOTmed News Associate Editor
Federal officials announced they were funding the development of five drugs designed to protect people from the horrors of radiation poisoning. The government's also financing studies to develop an improved version of another drug to treat people exposed to radioactive particles that could be released during a so-called dirty bomb attack.

Biomedical Advanced Research and Development Authority, or BARDA, a division of the Department of Health and Human Services, announced the roughly $60 million in funding in a series of releases Wednesday and Thursday.

Story Continues Below Advertisement

Ask Any Woman. She Wants a Better Breast Imaging Experience.

SoftVue Can Bring It. In today's healthcare environment, a positive patient experience is central in providing excellent patient care. This is where SoftVue comes in - click to read more>>>



About $56.3 million will go toward five contracts for a variety of drug companies and scientists working on countermeasures for acute radiation syndrome, or radiation sickness. When exposed to high doses of ionizing radiation -- such as from a nuclear bomb blast -- fast-reproducing cells in the gut, bone marrow, and lungs can be destroyed, which can in turn lead to internal bleeding, a depressed immune system and death over the following days or even weeks.

Winners of contracts include Neumedicines Inc., which got a $17 million award to study recombinant human interleukin-12 (rhuIL-12). Also called HemaMax, a 2008 BARDA-funded study showed it might be able to protect bone marrow from radiation.

Johnson City, Tenn.-based RxBio Inc. nabbed a two-year, $15 million contract to study Rx100, a small molecule-drug which might be able to prevent cells in the gut from dying if administered up to three days after radiation exposure. As with many of these radioprotectants under investigation, the company also said the proprietary substance -- which it says can be stored at room temperature and has a long shelf-life -- could help reduce GI chemotherapy side effects.

University of Arkansas for Medical Sciences also got a contract to research a drug, SOM230 or pasireotide, to protect the gut from radiation. The two-year, $4.5 million contract covers research on the substance, an analog of the hormone somatostatin, which was developed by pharama giant Novartis to treat various endrocrine tumors and Cushing's disease, a condition caused by the body's over-production of cortisol. The university researchers will try to provide results that Novartis can use to submit a Food and Drug Administration application for the drug, which apparently works by preventing pancreatic secretions that inflame the intestines.

Under a two-year, $3.1 million contract, Araim Pharmaceuticals, an Ossining, N.Y.-based biotech startup, will see if its drug, ARA 290, could help save lives up to 24 hours after radiation exposure. In tests on animals, the substance, which mimics a hormone found in the body and prevents cell death and inflammation, was found to protect against lethal doses of radiation, as well as to speed up wound healing, reduce brain, kidney and heart injuries from trauma or disease, and even improve learning.
  Pages: 1 - 2 >>

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED